Donald Abrams, M.D. is chief of Hematology and Oncology at San

Donald Abrams, M.D. is chief of Hematology and Oncology at San Francisco General Hospital and the co-author—with Andrew Weil—of Integrative Oncology (Oxford University Press). Abrams has extensive experience working with cancer and HIV/AIDS patients and is a pioneer in the field of medical cannabis research.

The U.S. government classifies cannabis—along with heroin and LSD—as a Schedule I drug, the most tightly restricted category of drugs in the United States. According to the federal government, Schedule I drugs are unsafe and have "no currently accepted medical use in treatment in the United States."

However, as medical cannabis proponents have pointed out since the Controlled Substances Act was passed by Congress in 1970, cannabis has been used medicinally for thousands of years, and there has never been a reported case of a marijuana overdose. Moreover, in recent years clinical researchers around the world have demonstrated the medicinal value of cannabis. Uploaded on Oct 14, 2010

April 28, 2012 - Seventh National Clinical Conference on Cannabis Therapeutics, hosted by Patients Out of Time - Founder and Director of the Arizona Center for

April 28, 2012 - Seventh National Clinical Conference on Cannabis Therapeutics, hosted by Patients Out of Time - Founder and Director of the Arizona Center for Integrative Medicine, College of Medicine at the University of Arizona, Andrew Weil, MD talks about challenges and the future of natural cannabis and cannabinoids in modern medicine, citing opiod-sparing effect; spasticity relief; neurological benefits for MS and ALS; modulation and quality of life.
Then panel moderator Clint Werner asks Dr. Weil about his early research on cannabis.